A Multicenter, Longitudinal, Observational Study in Children With Achondroplasia
Status: Recruiting
Location: See all (8) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY
The goal of this observational study is to collect the anthropometric parameters, clinical characteristics, related medical complications, health-related quality of life and treatments of children with ACH, and complete a natural history observation of ACH for at least 6 months and up to 2 years.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Maximum Age: 11
Healthy Volunteers: f
View:
• Prior to screening, the guardians and children with ACH (if applicable) must be willing and able to provide signed informed consent.
• Clinical diagnosis of ACH confirmed FGFR3 mutation by genetic testing.
• Male or female aged ≥2.5 to \<11 years old at screening.
• Tanner Stage 1 breast development for females or Tanner Stage 1 external genitalia development for males at screening.
• Ambulatory and able to stand without assistance.
Locations
Other Locations
China
Beijing Children's Hospital, Capital Medical University
RECRUITING
Beijing
Chengdu Women's and Children's Central Hospital
NOT_YET_RECRUITING
Chengdu
West China Second University Hospital, Sichuan University
ACTIVE_NOT_RECRUITING
Chengdu
Guangzhou Women and Childrens Medical Center
NOT_YET_RECRUITING
Guangzhou
Children's Hospital Zhejiang University School of Medicine
NOT_YET_RECRUITING
Hangzhou
Xin Hua Hospital Affiliatod to Shanghai Jiao Tong University School of Medicine
RECRUITING
Shanghai
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING
Wuhan
Henan Children's Hospital, Zhengzhou Children's Hospital
NOT_YET_RECRUITING
Zhengzhou
Contact Information
Primary
Jing Zhang
jing.zhang@abbisko.com
+86-15002126439
Time Frame
Start Date: 2025-06-20
Estimated Completion Date: 2039-04-30
Participants
Target number of participants: 260
Treatments
Children with Achondroplasia
Male or female aged ≥2.5 to \<11 years old at screening
Related Therapeutic Areas
Sponsors
Leads: Abbisko Therapeutics Co, Ltd